TOTAL: $M54.0 | ||||
Year to Date: $589.33M | ||||
Company | Partner | Amt. | Triggering | Details (Date) |
Cardiome | Astellas Pharma US Inc. | $10 | Milestone payment | Triggered by Astellas' resubmission of the NDA with the FDA seeking approval of the intravenous formulation of vernakalant hydrochloride for the acute conversion of atrial fibrillation (12/18) |
Cerus Corp. | BioOne Corp. (Singapore) | $5 | Milestone payment | Triggered by CE mark regulatory approval for the Intercept Blood System for plasma in Europe; Baxter Healthcare Corp. got $0.5M of the payment; another $5M milestone was expected in January (12/26) |
Isis | iCo Therapeutics Inc. (Canada) | ND | Milestone payment | Triggered by iCo's filing of an IND to begin trials of iCo-007 for treating eye diseases (12/21) |
Isis | Merck & Co. Inc. | $1 | Milestone payment | Triggered by Merck's initiation of clinical development of a compound discovered in their funded research collaboration (12/5) |
Micromet Inc. | Serono SA (Switzerland; NYSE:SRA) | $10 | Milestone payment | Triggered by completion of two single-agent Phase II trials of adecatumumab (MT201) in metastatic breast and prostate cancers (12/4) |
Neurocrine Biosciences Inc. (NBIX) | GlaxoSmithKline plc (UK) | $8 | Milestone payment | Triggered by GSK's initiation of Phase II trials of a corticotropin releasing factor R1 receptor antagonist in social anxiety disorder and irritable bowel syndrome (12/20) |
Targacept | AstraZeneca plc (UK) | $20 | Milestone payment | Triggered by AstraZeneca's decision to continue development of AZD3480 (TC-1734) in Alzheimer's disease and cognitive deficits in schizophrenia (12/27) |
Notes: | ||||
# Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
NYSE = New York Stock Exchange. | ||||